A childhood spent in the woods of Alaska helped develop Amy Emerson’s love of science and nature. She found her professional career in that intersection — studying genetics and cell biology — eventually landing in pharmaceutical development and research. Emerson’s experience spans decades. She’s worked at pharmaceutical companies in immunology, oncology and vaccines. Emerson’s path eventually led her to the work of Rick Doblin who founded the Multidisciplinary Association for Psychedelic Studies (MAPS), known globally for its work on developing MDMA-assisted psychotherapy for patients suffering from PTSD. Emerson serves as the CEO of the MAPS Public Benefit Corporation (MAPS PBC), which operates as a subsidiary of MAPS, and focuses on healing and well-being through psychedelic drug development, therapist training programs and prescription psychedelics. With the goal of bringing the first FDA-approved MDMA drug to those suffering from PTSD, Emerson sets a new stage for the future of mental health.